Morgan Stanley reaffirmed their equal weight rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research report sent to investors on Monday, Benzinga reports. Morgan Stanley currently has a $10.00 price target on the stock. Separately, JMP Securities lowered their target price on shares of Pharvaris from $23.00 to $20.00 and set a […]
Pharvaris (NASDAQ:PHVS – Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 18,900 shares, a decrease of 47.6% from the June 15th total of 36,100 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading […]
Pharvaris (NASDAQ:PHVS – Free Report) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 36,100 shares, a drop of 44.4% from the May 31st total of 64,900 shares. Based on an average daily volume of 28,900 shares, the short-interest ratio […]
Pharvaris N.V. (PHVS) announced Monday the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the on-demand treatment of hereditary angioedema or HAE, following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study.
ZUG, Switzerland, June 20, 2023 Pharvaris , a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of. | June 20, 2023